21:34 , Dec 16, 2016 |  BC Week In Review  |  Company News

Genocea, Checkmate deal

The companies partnered non-exclusively to use Genocea's ATLAS antigen identification screening system to profile about 20 advanced melanoma patients’ T cell responses in Checkmate’s Phase Ib trial of CMP-001 plus Keytruda pembrolizumab. Checkmate has exclusive,...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Cytos, Kuros deal

Kuros will reverse-merge with Cytos. The combined entity will be named Kuros Biosciences AG and focus on tissue repair and regeneration. Existing Kuros shareholders will own about 80% of the company, and Cytos shareholders will...
02:47 , Dec 4, 2015 |  BC Extra  |  Company News

Kuros reverse-merges with Cytos

Kuros Biosurgery AG (Zurich, Switzerland) plans to make its debut on the SIX Swiss Exchange through a reverse merger with Cytos Biotechnology AG (SIX:CYTN). The combined entity will be Kuros Biosciences AG. Kuros' management team,...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Cytos, Checkmate Pharma deal

Cytos granted Checkmate exclusive, worldwide rights to its platform technologies for virus-like particles (VLPs) and oligonucleotide synthesis, including CYT003. Checkmate plans to use the platform to develop oligonucleotide-based products in the field of immuno-oncology. Checkmate...
07:00 , Aug 17, 2015 |  BioCentury  |  Emerging Company Profile

Checkpoint and mate

Checkmate Pharmaceuticals Inc. is developing CpG oligonucleotide toll-like receptor 9 agonists to combine with checkpoint inhibitors to improve the proportion of patients whose cancers respond to treatment. Emerging from stealth last week with a $20...
07:00 , Aug 17, 2015 |  BioCentury  |  Finance

Entering the endgame

venBio may have seen its 2012 investment in Cytos Biotechnology AG (SIX:CYTN) go up in smoke, but the firm still could score a win from the biotech's virus-like particle (VLP) platform for cancer now that...
01:46 , Aug 13, 2015 |  BC Extra  |  Financial News

Checkmate debuts with $20M, Cytos deal

Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) raised $20 million in a series A round from Sofinnova Ventures and venBio. Checkmate also obtained an exclusive, worldwide license from Cytos Biotechnology AG (SIX:CYTN) to CYT003 , a virus-like...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Cytos, Novartis deal

Novartis will pay Cytos CHF4 million ($4.2 million) to eliminate payment obligations for CAD106 , an Alzheimer’s disease (AD) vaccine the companies discovered under a 2001 deal. Novartis is developing the vaccine containing beta amyloid...
03:24 , Jan 13, 2015 |  BC Extra  |  Company News

HBV play OnCore to merge with Tekmira

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) surged $8.98 (57%) to $24.68 on Monday after announcing plans to merge with OnCore Biopharma Inc. (Doylestown, Pa.). Under the proposed merger, OnCore would become a wholly owned subsidiary of...